Request for Information – Commonsense Policy Options to Lower Drug Prices for Patients
August 17, 2026 The Honorable Ron Wyden Ranking Member, Senate Committee on Finance 219 Dirksen Senate Office Building Washington, DC 20510 Re: Request for Information – Commonsense Policy Options to Lower Drug Prices for Patients Dear Ranking Member Wyden and Members of the Senate Finance Committee Minority, On behalf of the Pharmaceutical Industry Labor-Management Association […]
CMS-4215-P – Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
August 17, 2026 The Honorable Mehmet Oz Administrator, Centers for Medicare and Medicaid Services U.S. Department of Health and Human Services Attn: CMS-4215-P, P.O. Box 8013, Baltimore, MD 21244 Re: CMS-4215-P – Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Dear Administrator Oz, On behalf of the Pharmaceutical Industry Labor-Management Association (PILMA) […]
Section 301 Investigation of Germany’s Pharmaceutical Pricing Policies — Docket ID USTR-2026-0463
August 9, 2026 Ambassador Jamieson GreerUnited States Trade Representative600 17th Street NWWashington, DC 20508Re: Section 301 Investigation of Germany’s Pharmaceutical Pricing Policies — DocketID USTR-2026-0463Dear Ambassador Greer,I write today to voice my support of the United States Trade Representative’s decision toinitiate a Section 301 investigation into Germany’s pharmaceutical pricing policies. I submitthese comments in my […]
PILMA Letter to HELP Committee: MAPIA
June 15, 2026 Dear Members of the Senate Committee on Health, Education, Labor and Pensions: The Pharmaceutical Industry Labor-Management Association (PILMA), a coalition uniting the biopharmaceutical industry and America’s building trades unions around a shared commitment to medical innovation and high-quality union jobs, strongly opposes the Medication Affordability and Patent Integrity Act (S. 2658). As […]
PILMA Statement on MFN Drug Pricing Reconciliation Bill Amendment
May 20, 2026 The Pharmaceutical Industry Labor-Management Association (PILMA) issued the following statement in response to the potential inclusion of a Most Favored Nation drug pricing proposal ahead of an anticipated vote on the Senate’s budget reconciliation bill. While we believe it is crucial that policymakers prioritize making healthcare more affordable for American families, importing […]
PILMA Letter on Senate HELP Drug Pricing Hearing
April 16, 2026 The Honorable Bill Cassidy, M.D. Chairman Committee on Health, Education, Labor, and Pensions United States Senate 428 Dirksen Senate Office Building Washington, DC 20510 The Honorable Bernie Sanders Ranking Member Committee on Health, Education, Labor, and Pensions United States Senate 428 Dirksen Senate Office Building Washington, DC 20510 Re: Full Committee Hearing […]
PILMA Letter of Opposition to 340B Expansion in New York.
The Honorable Kathy Hochul Governor of New York New York State Capitol Building Albany, NY 12224 Dear Governor Hochul, On behalf of the Pharmaceutical Industry Labor-Management Association (PILMA), I write to express strong opposition to the inclusion of 340B expansion language in the final New York State budget, including the language reflected in A.6222 (Paulin) […]
PILMA Letter on 340B Legislation in Minnesota
February 25, 2026 Senator Erin Murphy 95 University Ave W Minnesota Senate Building, Room 3113 St. Paul, MN 55115 Representative Lisa Demuth C Centennial Office Building, 2nd Floor St. Paul, MN 55115 Dear Majority Leader Murphy and Speaker Demuth: On behalf of the Pharmaceutical Industry Labor-Management Association (PILMA), a labor-management partnership representing unions and biopharmaceutical […]
PILMA Letter on Virginia PDAB Legislation
The Honorable Abigail Spanberger Governor of Virginia 1111 East Broad Street Richmond, VA 23219 Dear Governor Spanberger, On behalf of the Pharmaceutical Industry Labor-Management Association (PILMA), we respectfully urge you to oppose HB 483 / SB 271, legislation that would establish a Prescription Drug Affordability Board. We recognize that the cost of prescription drugs is […]
PILMA Applauds Bipartisan PBM Reform in Congressional Appropriations Package
February 3, 2026 Washington, D.C. – The Pharmaceutical Industry Labor-Management Association (PILMA) applauds Congress for passing critical pharmacy benefit manager (PBM) reform legislation as part of the bipartisan spending package now headed to the President’s desk. “After years of advocacy, meaningful PBM reform has finally crossed the finish line,” said AJ Stokes, PILMA’s Executive Director. […]